Ojemda

Oncology

Day One's big bet on tovorafenib just keeps paying off

Now set to be acquired by Servier for $2.5 billion, Day One Bio proves how far a mission-driven biotech with a strong team and good timing can go.

News

Servier snaps up cancer biotech Day One in $2.5bn deal

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

News

CHMP backs Ipsen drug for childhood brain cancer

Ipsen's Ojemda is on course to become the first targeted medicine in the EU for some children with a form of brain cancer known as low-grade glioma.

News

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

Day One's big bet on tovorafenib just keeps paying off

Servier snaps up cancer biotech Day One in $2.5bn deal

CHMP backs Ipsen drug for childhood brain cancer

Ipsen builds again, licensing Day One glioma drug

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

Ojemda

Editor's Picks